Found: 13
Select item for more details and to access through your institution.
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1311, doi. 10.1007/s10637-013-9978-z
- By:
- Publication type:
- Article
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 12, p. 1595, doi. 10.1002/ajh.26361
- By:
- Publication type:
- Article
Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 2, p. 199, doi. 10.1002/ajh.24230
- By:
- Publication type:
- Article
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
- Published in:
- PLoS ONE, 2018, v. 13, n. 8, p. 1, doi. 10.1371/journal.pone.0202272
- By:
- Publication type:
- Article
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
- Published in:
- 2022
- By:
- Publication type:
- corrected article
Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy.
- Published in:
- Current Oncology Reports, 2020, v. 22, n. 11, p. N.PAG, doi. 10.1007/s11912-020-00974-z
- By:
- Publication type:
- Article
Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study.
- Published in:
- British Journal of Haematology, 2015, v. 171, n. 3, p. 373, doi. 10.1111/bjh.13592
- By:
- Publication type:
- Article
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 7, p. 1025, doi. 10.1002/cncr.29169
- By:
- Publication type:
- Article
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance).
- Published in:
- British Journal of Clinical Pharmacology, 2014, v. 78, n. 5, p. 1005, doi. 10.1111/bcp.12427
- By:
- Publication type:
- Article
Genomewide Meta‐Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent‐Induced Sensory Peripheral Neuropathy.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 3, p. 625, doi. 10.1002/cpt.1958
- By:
- Publication type:
- Article
A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer using Genome‐Wide Genotyping Data from CALGB 40502 (Alliance).
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 738, doi. 10.1002/cpt.1241
- By:
- Publication type:
- Article